Vera Therapeutics (VERA) Expected to Announce Quarterly Earnings on Wednesday

Vera Therapeutics (NASDAQ:VERA - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 19th. Analysts expect the company to announce earnings of ($0.81) per share for the quarter.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11. On average, analysts expect Vera Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Vera Therapeutics Stock Performance

VERA stock opened at $28.36 on Wednesday. The stock has a market cap of $1.80 billion, a P/E ratio of -10.87 and a beta of 1.17. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The firm has a 50 day simple moving average of $33.89 and a 200 day simple moving average of $39.84. Vera Therapeutics has a 52 week low of $25.99 and a 52 week high of $51.61.

Insider Transactions at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $43.07, for a total value of $753,725.00. Following the transaction, the chief executive officer now owns 85,942 shares of the company's stock, valued at $3,701,521.94. This trade represents a 16.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 21.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have recently commented on VERA. JPMorgan Chase & Co. lowered their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a report on Tuesday, March 4th. Guggenheim boosted their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. The Goldman Sachs Group began coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $58.00 price target on the stock. Wells Fargo & Company began coverage on shares of Vera Therapeutics in a report on Thursday, November 21st. They set an "overweight" rating and a $70.00 price target on the stock. Finally, Wolfe Research began coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price target on the stock. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Vera Therapeutics has a consensus rating of "Buy" and a consensus target price of $64.67.

Remove Ads

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.